Clinical response and pathway-specific correlates following TIGIT–LAG3 blockade in myeloma: the MyCheckpoint randomized clinical trial
Year: 2024
Type: article
Study design: Clinical Trial
Source: Nature Cancer
Institutions: Tisch Cancer Institute, Memorial Sloan Kettering Cancer Center, Levine Cancer Institute, Emory University, Winship Cancer Institute, U-M Rogel Cancer Center, Hackensack University Medical Center, Washington University in St. Louis, Multiple Myeloma Research Foundation, Children's Healthcare of Atlanta
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: green
Funders: U.S. Department of Health and Human Services, Multiple Myeloma Research Foundation, Amgen, Pfizer, Sanofi, Leukemia and Lymphoma Society, Paula and Rodger Riney Foundation, National Institutes of Health, Genentech, National Cancer Institute, National Institute of Arthritis and Musculoskeletal and Skin Diseases
Awards: B cells in autoimmunity following checkpoint blockade therapy, G1075614049, G1229558712, G1296706837, G1489263424, G1823531124, G2920985788, G2948137344, G3697868392, G4029350880, G4102770861, Targeting microbial triggers of gammopathy for immunoprevention, G5135982761, G6516949535, B cell depletion to prevent autoimmunity, HARNESSING HOST RESPONSE TO PREVENT MYELOMA, G6696228679, Winship Cancer Institute Cancer Center Support Grant, G9000003249, G9000017109, G9000060737, Cancer Center Support Grant, Improving immune modulation for smoldering myeloma
OpenAlex ID: W4401894608